No. |
DrugBank |
Drug (Description in trials) [Number of descriptions] |
KEGG DRUG * | KEGG GENES * [Number of genes] |
KEGG PATHWAY [Number of pathways] |
Disease ID * [Number of diseases] |
1 | Abacavir | [5] Abacavir; Abacavir 300mg twice daily; Abacavir sulfate; Abacavir sulfate, lamivudine and zidovudine; Reverse transcriptase inhibitors: zidovudine, lamivudine, abacavir; | D00891 D07057 |
- |
- |
[4] 2, 135, 265, 325 |
2 | Acetate | [76] 11c acetate; 11c-acetate; 20mg/0.5ml glatiramer acetate; 40 mg glatiramer acetate; [n-trans-3-hexenoyl] human growth hormone releasing factor (1-44) acetate; Abiraterone acetate; Acetate; Bazedoxifene acetate; Betamethasone sodium phosphate/betamethasone acetate (celestone® soluspan®), 30 mg im once a day for four days; Caspofungin acetate; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Cortisone acetate; Cosyntropin acetate; Cyclophosphamide/glatiramer acetate; Delmitide acetate; Depot leuprolide acetate 3.75 mg; Desmopressin acetate; Desmopressin acetate trihydrate; Dirucotide acetate; Experimental glatiramer acetate; Flecainide acetate; Glatiramer acetate; Glatiramer acetate (copaxone®); Glatiramer acetate (db); Glatiramer acetate (ga); Glatiramer acetate (ga) 40 mg; Glatiramer acetate (ol); Glatiramer acetate 150mg enteric coated tablets; Glatiramer acetate 150mg enteric-coated (gastro-resistant) tablets; Glatiramer acetate 20 mg; Glatiramer acetate 20 mg, with mitoxantrone; Glatiramer acetate 20 mg/0.5 ml; Glatiramer acetate 40 mg; Glatiramer acetate injection with oral cetirizine hydrochloride; Glatiramer acetate with minocycline; Glatiramer acetate, (copaxone®); Glatiramer acetate, ifn-beta 1a (im), ifn-beta 1a (subcutaneous), and ifn-beta 1b; Glatiramer acetate, n-acetylcysteine; Gonadorelin acetate and triptorelin acetate; Human interferon beta-1a and glatiramer acetate; Hydrocortisone sodium acetate; L-lysyl-d-prolyl-l-threonine acetate; Lanreotide acetate; Leuprolide acetate (la); Leuprolide acetate 11.25 mg; Leuprolide acetate 3 month depot; Leuprolide acetate 30 mg; Leuprolide acetate 45 mg; Leuprolide acetate depot; Leuprorelin acetate; Leuprorelin acetate 3.75mg injection; Loestrin (norethindrone acetate and ethinyl estradiol); Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 µg ethinyl estradiol); Luphere depot 3.75mg(leuprolide acetate 3.75mg); Lupron (leuprolide acetate); Macimorelin acetate; Megestrol acetate; Megestrol acetate tablet; Nomegestrol acetate; Phosphate and betamethasone acetate, 2 ml.; Plovamer acetate; Prednisolone acetate; Prednisone acetate; Prednisone acetate tablets; Sodium acetate; Sodium-[o-[(2,6-dichlorophenyl)-amino]-phenyl]-acetate; Sotrastaurin (inn) acetate; Tetracosactide acetate; Tocopherol acetate; Tocopheryl acetate; Triptorelin acetate and gonadorelin acetate; Ulipristal acetate; Zinc acetate; Zinc acetate (20mg/d); Zinc acetate dihydrate; Zuretinol acetate; | - |
- |
- |
[40] 1, 2, 6, 10, 13, 35, 40, 46, 49, 51, 60, 64, 70, 71, 73, 75, 76, 78, 81, 83, 85, 86, 88, 90, 96, 97, 113, 145, 156, 162, 171, 206, 222, 224, 225, 235, 265, 288, 298, 299 |
3 | Acetylcarnitine | [1] Acetylcarnitine; | - |
- |
- |
[3] 2, 265, 298 |
4 | Aldesleukin | [3] Aldesleukin; Interleukin-2 (aldesleukin).; Low-dose aldesleukin (proleukin®); | D00748 |
[3] IL2RA, IL2RB, IL2RG |
[14] Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Primary immunodeficiency, Th1 and Th2 cell differentiation, Th17 cell differentiation, Transcriptional misregulation in cancer, Viral protein interaction with cytokine and cytokine receptor |
[4] 2, 49, 65, 97 |
5 | Anakinra | [8] Anakinra; Anakinra (kineret®); Anakinra (r-methuil-1ra); Anakinra / kineret; Anakinra and peg stnf-r1; Kineret® (anakinra); Kineret® or anakinra; Response to anakinra associated with methotrexate; | D02934 |
[2] IL1R1, IL1R2 |
[15] Amoebiasis, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Pathogenic Escherichia coli infection, Prostate cancer, Shigellosis, Th17 cell differentiation, Transcriptional misregulation in cancer |
[17] 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 |
6 | Arimoclomol | [1] Arimoclomol; | D11374 |
- |
- |
[3] 2, 15, 19 |
7 | Arundic acid | [1] Arundic acid; | D06296 |
- |
- |
[1] 2 |
8 | Baclofen | [5] Aert, (r)-baclofen; Baclofen; Baclofen 20 mg; Baclofen ir; Rs-baclofen; | D00241 |
[2] GABBR1, GABBR2 |
[7] Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway |
[5] 2, 10, 13, 18, 149 |
9 | Basiliximab | [1] Basiliximab; | D03058 |
[1] IL2RA |
[11] Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
[7] 2, 50, 65, 66, 97, 222, 228 |
10 | Betamethasone | [6] Betamethasone; Betamethasone acibutate; Betamethasone sodium phosphate/betamethasone acetate (celestone® soluspan®), 30 mg im once a day for four days; Intra-articular compound betamethasone; Intraarticular betamethasone; Phosphate and betamethasone acetate, 2 ml.; | D00244 D00972 D01357 D01402 D01637 D02032 D02286 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[6] 2, 46, 65, 90, 96, 235 |
11 | Biotin | [2] Biotin; D-biotin; | D00029 |
- |
- |
[3] 2, 13, 20 |
12 | Bosutinib | [1] Bosutinib; | D03252 |
[2] ABL1, SRC |
[45] Adherens junction, Axon guidance, Bacterial invasion of epithelial cells, Bladder cancer, C-type lectin receptor signaling pathway, Cell cycle, Chemokine signaling pathway, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Epithelial cell signaling in Helicobacter pylori infection, ErbB signaling pathway, Estrogen signaling pathway, Fluid shear stress and atherosclerosis, Focal adhesion, GABAergic synapse, Gap junction, GnRH signaling pathway, Hepatitis B, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, Kaposi sarcoma-associated herpesvirus infection, MicroRNAs in cancer, Mitophagy - animal, Neurotrophin signaling pathway, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Platelet activation, Prolactin signaling pathway, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Shigellosis, Thyroid hormone signaling pathway, Tight junction, Tuberculosis, VEGF signaling pathway, Viral carcinogenesis, Viral myocarditis, Yersinia infection |
[2] 2, 67 |
13 | Botulinum Toxin Type B | [3] Botulinum toxin type b; Botulinum toxin type b (2500 units / vial); Botulinum toxin type b (myobloc); | D02735 |
[1] SNAP25 |
[2] Insulin secretion, Synaptic vesicle cycle |
[3] 2, 6, 51 |
14 | Botulinum toxin type A | [3] Botulinum toxin type a; Botulinum toxin type a (nabota®) injection into the gastrocnemius muscle; Clostridium botulinum toxin type a; | D00783 |
[1] SNAP25 |
[2] Insulin secretion, Synaptic vesicle cycle |
[13] 2, 5, 6, 7, 13, 15, 17, 36, 51, 70, 113, 149, 226 |
15 | Butylphthalide | [1] Butylphthalide; | - |
- |
- |
[2] 2, 6 |
16 | Caffeine | [5] Caffeine; Caffeine 100 mg; Caffeine 100-200 mg bid; Caffeine alkaloid; Dextromethorphan and caffeine; | D00528 D01453 |
[11] ADORA1, ADORA2A, PDE1B, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A |
[22] Alcoholism, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Parkinson disease, Progesterone-mediated oocyte maturation, Purine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Taste transduction, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
[6] 2, 6, 46, 78, 96, 97 |
17 | Cannabidiol | [6] Cannabidiol; Cannabidiol (cbd); Cannabidiol / dronabinol capsule 5 mg+2,5 mg; Cannabidiol capsule 5 mg; Cannabidiol oral solution; Cannabidiol tablet 10 mg; | D10915 |
[2] CNR1, CNR2 |
[4] Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
[14] 2, 6, 13, 46, 95, 96, 97, 140, 144, 145, 157, 158, 193, 271 |
18 | Capsaicin | [4] Capsaicin; Capsaicin challenge; Capsaicin vapor; Qutenza (8% capsaicin); | D00250 |
[1] TRPV1 |
[2] Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
[6] 2, 6, 19, 86, 113, 226 |
19 | Carbidopa | [60] Accordion pill carbidopa/levodopa; Accordion pill™ carbidopa/levodopa; Accordion pill™ carbidopa/levodopa 50/400 mg; Accordion pill™ carbidopa/levodopa 50/500 mg; Capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg); Carbidopa; Carbidopa 20 mg; Carbidopa 27.5 mg; Carbidopa 65 mg capsule; Carbidopa and levodopa 25mg/100mg; Carbidopa fu; Carbidopa levodopa; Carbidopa monohydrate; Carbidopa, levodopa, entacapone; Carbidopa- levodopa; Carbidopa-levodopa; Carbidopa/l-dopa; Carbidopa/l-dopa/entacapone; Carbidopa/levodopa; Carbidopa/levodopa, immediate release; Carbidopa/levodopa/entacapone; Comparator: carbidopa; Continuous intrajejunal infusion of levodopa-carbidopa; Controlled-release levodopa / carbidopa; Entacapone and carbidopa; Immediate release carbidopa/levodopa; Immediate release carbidopa/levodopa 25/100 mg; Levodopa and carbidopa; Levodopa and carbidopa sc solution; Levodopa and carbidopa solution for sc administration; Levodopa carbidopa (lc) oral encapsulated immediate release (ir) tablets; Levodopa carbidopa intestinal gel (lcig); Levodopa, carbidopa, entacapone; Levodopa, carbidopa, odm-104; Levodopa-carbidopa; Levodopa-carbidopa (lc) oral encapsulated immediate release (ir) tablets; Levodopa-carbidopa immediate release (lc-ir) tablets; Levodopa-carbidopa intestinal gel; Levodopa-carbidopa multilayer extended release tablet; Levodopa-carbidopa xl tablet (m); Levodopa-carbidopa-entacapone; Levodopa/carbidopa; Levodopa/carbidopa (4:1); Levodopa/carbidopa (sinemet); Levodopa/carbidopa 100/25; Levodopa/carbidopa hydrate; Levodopa/carbidopa solution; Levodopa/carbidopa(200mg/50mg); Levodopa/carbidopa/entacapone; Nd0612 (levodopa/carbidopa solution); Odm-101 105mg carbidopa; Odm-101 65mg carbidopa; Oral levodopa and carbidopa; Oral levodopa/carbidopa; Sinemet (levodopa/carbidopa); Sinemet plus (levodopa/carbidopa); Sinemet® controlled release (carbidopa/levodopa); Stalevo (levodopa/ carbidopa/ entacapone); Stalevo (levodopa/carbidopa/entacapona); Xp21279 and carbidopa (experimental); | D00558 |
[1] DDC |
[9] Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
[8] 2, 4, 6, 13, 17, 90, 164, 201 |
20 | Carbonate ion | - | - |
- |
- |
[10] 2, 13, 17, 19, 46, 75, 96, 127, 235, 299 |
21 | Ceftriaxone | [1] Ceftriaxone; | D00924 D07659 |
- |
- |
[3] 2, 6, 97 |
22 | Celecoxib | [7] Celecoxib; Celecoxib (celebrex); Celecoxib 200 milligrams; Celecoxib 200mg capsule; Celecoxib 400 milligrams; Celecoxib, celebrex®; Fixed dose combination ciprofloxacin/celecoxib; | D00567 |
[1] PTGS2 |
[20] Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
[9] 2, 3, 34, 46, 70, 89, 96, 161, 271 |
23 | Cimetidine | [2] Cimetidine; Cimetidine plus dexpramipexole; | D00295 D03503 |
[1] HRH2 |
[3] Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand-receptor interaction |
[1] 2 |
24 | Ciprofloxacin | [14] Cipro (ciprofloxacin, bayq3939); Ciprofloxacin; Ciprofloxacin (cipro inhale, bayq3939); Ciprofloxacin (cipro, bayq3939); Ciprofloxacin (ciproxin); Ciprofloxacin dispersion for inhalation; Ciprofloxacin dpi; Ciprofloxacin for inhalation; Ciprofloxacin hydrochloride; Ciprofloxacin hydrochloride monohydrate; Fixed dose combination ciprofloxacin/celecoxib; Oral ciprofloxacin; Oral ciprofloxacin plus inhaled colistin; Po ciprofloxacin; | D00186 D02216 |
- |
- |
[5] 2, 60, 96, 97, 299 |
25 | Colchicine | [3] Colchicine; Colchicine 1 mg oral tablet; Colchicine sprinkle capsules; | D00570 |
[9] TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 |
[3] Gap junction, Pathogenic Escherichia coli infection, Phagosome |
[5] 2, 42, 56, 93, 266 |
26 | Copper | [4] Copper; Copper histidinate; Copper histidine; Zinc and copper; | - |
- |
- |
[4] 2, 169, 170, 171 |
27 | Corticotropin | [8] Corticotropin; Corticotropin releasing hormone; Corticotropin-releasing hormone; H.p. acthar gel (repository corticotropin injection); H.p. acthar® gel (repository corticotropin injection); Ovine corticotropin-releasing hormone (ocrh); Repository corticotropin injection; Repository corticotropin injection -treatment extension; | D00146 |
[1] MC2R |
[5] Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
[12] 2, 13, 46, 49, 50, 66, 75, 78, 84, 145, 193, 222 |
28 | Creatine | [4] Creatine; Creatine monohydrate; Creatine-13c; Pyruvate, creatine, niacinamide; | - |
- |
- |
[12] 1, 2, 5, 6, 8, 13, 46, 49, 50, 113, 156, 201 |
29 | Creatinine | [1] Creatinine; | D03600 |
- |
- |
[3] 2, 46, 60 |
30 | Cupric Chloride | - | D03612 |
- |
- |
[4] 2, 169, 170, 171 |
31 | Darunavir | [1] Darunavir; | D03656 |
- |
- |
[1] 2 |
32 | Deferiprone | [7] Deferiprone; Deferiprone (ferriprox); Deferiprone 600 mg delayed release tablet; Deferiprone 80 mg/ml oral solution; Deferiprone 80 mg/ml oral solution (ferriprox); Deferiprone oral solution; Ferrprox (deferiprone); | D07416 |
- |
- |
[5] 2, 6, 120, 122, 233 |
33 | Dexmedetomidine | [8] Dexmedetomidine; Dexmedetomidine 1; Dexmedetomidine 2; Dexmedetomidine 3; Dexmedetomidine and fentanyl; Dexmedetomidine group; Dexmedetomidine hydrochloride; Dexmedetomidine hydrochloride infusion; | D00514 D01205 |
[3] ADRA2A, ADRA2B, ADRA2C |
[2] Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
[11] 2, 4, 6, 21, 34, 70, 113, 212, 215, 226, 280 |
34 | Dexpramipexole | [5] Cimetidine plus dexpramipexole; Dexpramipexole; Dexpramipexole (dose 1); Dexpramipexole (dose 2); Dexpramipexole dichydrochloride; | D09886 |
[5] DRD1, DRD2, DRD3, DRD4, DRD5 |
[11] Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
[1] 2 |
35 | Dextran | [4] Dextran; Dextran sulfate sodium; Iron dextran; Iron(iii)- hydroxide dextran complex; | D00060 |
- |
- |
[5] 2, 62, 79, 96, 97 |
36 | Dextromethorphan | [9] Dextromethorphan; Dextromethorphan 30 mg; Dextromethorphan and caffeine; Dextromethorphan hbr and quinidine sulfate; Dextromethorphan hydrobromide; Dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg; Dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg; Dextromethorphan/quinidine 20mg/10mg (dm/q 20mg/10mg); Dimebon + dextromethorphan; | D00848 D03742 D03744 |
[5] GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
[17] Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
[9] 2, 6, 8, 13, 46, 78, 96, 97, 156 |
37 | Dolutegravir | [1] Dolutegravir; | D10066 |
- |
- |
[1] 2 |
38 | Dronabinol | [4] Cannabidiol / dronabinol capsule 5 mg+2,5 mg; Dronabinol; Dronabinol capsule 2,5 mg; Dronabinol capsule 2.5. mg; | D00306 |
[2] CNR1, CNR2 |
[4] Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
[5] 2, 13, 46, 271, 298 |
39 | Edaravone | [1] Edaravone; | D01552 |
- |
- |
[2] 2, 22 |
40 | Eperisone | [1] Eperisone; | D01671 D07898 |
- |
- |
[1] 2 |
41 | Erythropoietin | [4] Erythropoietin; Erythropoietin human recombinant (eporh); Recombinant human erythropoietin; Recombinant human erythropoietin(rhepo); | D03231 |
[1] EPOR |
[5] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
[9] 2, 6, 13, 22, 46, 47, 70, 95, 96 |
42 | Escitalopram | [3] Escitalopram; Escitalopram oxalate antidepressant; Oral escitalopram; | D02567 D07704 D07913 |
[1] SLC6A4 |
[2] Serotonergic synapse, Synaptic vesicle cycle |
[3] 2, 6, 13 |
43 | Esketamine | [2] Esketamine; Esketamine hydrochloride; | D07283 |
[5] GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
[17] Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
[3] 2, 4, 70 |
44 | Ethanol | [7] Andrographis paniculata (ethanol extract); Ethanol; Ethanol (96 per cent); Ethanol 96% gel; Ethanol 98% solution; Ethanol bp; Ethanol gel; | D00068 D02798 D04855 D06542 |
- |
- |
[49] 2, 11, 13, 14, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 58, 61, 63, 64, 65, 66, 81, 84, 85, 86, 88, 95, 96, 97, 113, 145, 162, 164, 222, 224, 228, 251, 279, 280, 283, 284, 285, 288, 298, 299, 300, 331 |
45 | Ezogabine | [4] Ezogabine; Ezogabine (us only); Ezogabine/retigabine; Retigabine/ezogabine; | D09569 |
[5] KCNQ1, KCNQ2, KCNQ3, KCNQ4, KCNQ5 |
[6] Adrenergic signaling in cardiomyocytes, Cholinergic synapse, Gastric acid secretion, Pancreatic secretion, Protein digestion and absorption, Vibrio cholerae infection |
[2] 2, 144 |
46 | Fasudil | [1] Fasudil; | D07941 |
[2] ROCK1, ROCK2 |
[22] Axon guidance, Chemokine signaling pathway, Focal adhesion, Human cytomegalovirus infection, Leukocyte transendothelial migration, MicroRNAs in cancer, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Platelet activation, Proteoglycans in cancer, Regulation of actin cytoskeleton, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, TGF-beta signaling pathway, Tight junction, Vascular smooth muscle contraction, Wnt signaling pathway, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway |
[1] 2 |
47 | Febuxostat | [1] Febuxostat; | D01206 |
[1] XDH |
[5] Caffeine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Peroxisome, Purine metabolism |
[3] 2, 6, 13 |
48 | Filgrastim | [6] Ep2006 (filgrastim); Filgrastim; Filgrastim (g-csf); Filgrastim hexal; Filgrastim, alemtuzumab; Granulocyte colony-stimulating factor (filgrastim); | D03235 |
[1] CSF3R |
[5] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
[28] 2, 6, 13, 16, 25, 26, 28, 34, 35, 36, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 85, 96, 113, 164, 283, 284, 285, 331 |
49 | Fingolimod | [6] 0,5 mg fingolimod; Fingolimod; Fingolimod (fty720); Fingolimod 0.5 mg; Fingolimod 1.25 mg; Fingolimod hydrochloride; | D10001 |
[1] S1PR1 |
[3] FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
[4] 2, 13, 14, 156 |
50 | Glatiramer | [23] 20mg/0.5ml glatiramer acetate; 40 mg glatiramer acetate; Cyclophosphamide/glatiramer acetate; Experimental glatiramer acetate; Glatiramer; Glatiramer acetate; Glatiramer acetate (copaxone®); Glatiramer acetate (db); Glatiramer acetate (ga); Glatiramer acetate (ga) 40 mg; Glatiramer acetate (ol); Glatiramer acetate 150mg enteric coated tablets; Glatiramer acetate 150mg enteric-coated (gastro-resistant) tablets; Glatiramer acetate 20 mg; Glatiramer acetate 20 mg, with mitoxantrone; Glatiramer acetate 20 mg/0.5 ml; Glatiramer acetate 40 mg; Glatiramer acetate injection with oral cetirizine hydrochloride; Glatiramer acetate with minocycline; Glatiramer acetate, (copaxone®); Glatiramer acetate, ifn-beta 1a (im), ifn-beta 1a (subcutaneous), and ifn-beta 1b; Glatiramer acetate, n-acetylcysteine; Human interferon beta-1a and glatiramer acetate; | D04318 |
[20] HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G |
[32] Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
[4] 2, 13, 96, 156 |
51 | Gold | [3] Gold; Gold nanocrystals; Sodium aurothiomalate (intramuscular gold); | - |
- |
- |
[5] 2, 6, 13, 46, 171 |
52 | Guanabenz | [2] Guanabenz; Guanabenz acetato; | D04375 |
[3] ADRA2A, ADRA2B, ADRA2C |
[2] Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
[2] 2, 13 |
53 | Human Serum Albumin | [4] Human serum albumin; Human serum albumin (hsa) fused to recombinant human growth hormone (hgh); Human serum albumin (hsa) fused to somatropin; Recombinant human serum albumin (hsa) fused to human growth hormone (hgh); | D05424 |
- |
- |
[3] 2, 78, 96 |
54 | Human interleukin-2 | [2] Human interleukin-2; Recombinant human interleukin-2 (rhil-2); | - |
- |
- |
[14] 2, 13, 35, 46, 49, 51, 55, 56, 63, 65, 95, 96, 97, 271 |
55 | Ibudilast | [1] Ibudilast; | D01385 |
[8] CYSLTR1, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PTGIR |
[16] Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action, Platelet activation, Progesterone-mediated oocyte maturation, Purine metabolism, Regulation of lipolysis in adipocytes, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
[2] 2, 13 |
56 | Immune Globulin Human | - | - |
- |
- |
[20] 2, 11, 13, 14, 17, 18, 35, 38, 39, 43, 45, 49, 50, 51, 63, 65, 85, 164, 296, 309 |
57 | Inosine | [2] 1) inosine 5'-monophosphate; Inosine; | D00054 |
- |
- |
[4] 2, 6, 13, 17 |
58 | Iodide I-123 | - | - |
- |
- |
[2] 2, 6 |
59 | Ioflupane I-123 | [1] Ioflupane i 123; | D10014 |
- |
- |
[3] 2, 5, 6 |
60 | Lacosamide | [1] Lacosamide; | D07299 |
[2] SCN3A, SCN9A |
[1] Taste transduction |
[3] 2, 46, 149 |
61 | Lactose | [3] Lactose; Lactose in water; Lactose monohydrate; | D00046 D03226 |
- |
- |
[6] 2, 6, 13, 97, 228, 310 |
62 | Lamivudine | [7] Abacavir sulfate, lamivudine and zidovudine; Combivir (zidovudine [azt] / lamivudine [3tc]); Lamivudine; Lamivudine/zidovudine; Lopinavir/ritonavir + zidovudine + lamivudine; Reverse transcriptase inhibitors: zidovudine, lamivudine, abacavir; Zidovudine/lamivudine; | D00353 |
- |
- |
[7] 2, 26, 42, 46, 135, 265, 325 |
63 | Lenograstim | [3] Granocyte - 34 million iu (lenograstim rhug-csf); Granocyte lenograstim; Lenograstim; | D03247 |
[1] CSF3R |
[5] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
[3] 2, 57, 65 |
64 | Leuprolide | [11] Depot leuprolide acetate 3.75 mg; Leuprolide; Leuprolide (gnrh agonists); Leuprolide acetate (la); Leuprolide acetate 11.25 mg; Leuprolide acetate 3 month depot; Leuprolide acetate 30 mg; Leuprolide acetate 45 mg; Leuprolide acetate depot; Luphere depot 3.75mg(leuprolide acetate 3.75mg); Lupron (leuprolide acetate); | D00989 D08113 |
[1] GNRHR |
[2] GnRH signaling pathway, Neuroactive ligand-receptor interaction |
[5] 1, 2, 3, 51, 76 |
65 | Levetiracetam | [1] Levetiracetam; | D00709 |
[1] SV2A |
[1] ECM-receptor interaction |
[4] 2, 4, 6, 13 |
66 | Levodopa | [87] Accordion pill carbidopa/levodopa; Accordion pill™ carbidopa/levodopa; Accordion pill™ carbidopa/levodopa 50/400 mg; Accordion pill™ carbidopa/levodopa 50/500 mg; Capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg); Carbidopa and levodopa 25mg/100mg; Carbidopa levodopa; Carbidopa, levodopa, entacapone; Carbidopa- levodopa; Carbidopa-levodopa; Carbidopa/levodopa; Carbidopa/levodopa, immediate release; Carbidopa/levodopa/entacapone; Comparator: levodopa; Continuous intrajejunal infusion of levodopa-carbidopa; Controlled-release levodopa / carbidopa; Immediate release carbidopa/levodopa; Immediate release carbidopa/levodopa 25/100 mg; Intravenous levodopa; Iv levodopa; Levodopa; Levodopa (delivered intravenously); Levodopa (drug), intraduodenal administration; Levodopa (l-dopa); Levodopa (l-dopa) + standard care; Levodopa / benserazid; Levodopa / benserazide 200 + 50 mg; Levodopa 100 mg / benserazide 25 mg; Levodopa 100 mg a cap; Levodopa 125 mg a cap; Levodopa 150 mg a cap; Levodopa 25mg/100mg; Levodopa 75 mg a cap; Levodopa acute challenge; Levodopa and carbidopa; Levodopa and carbidopa sc solution; Levodopa and carbidopa solution for sc administration; Levodopa and decarboxylase inhibitor; Levodopa and domperidone; Levodopa benserazide madopar; Levodopa benserazide teva italia; Levodopa carbidopa (lc) oral encapsulated immediate release (ir) tablets; Levodopa carbidopa intestinal gel (lcig); Levodopa cr (controlled release); Levodopa cyclops; Levodopa dc.it fu; Levodopa dispersible; Levodopa infusion; Levodopa mr; Levodopa powder for inhalation; Levodopa test; Levodopa, carbidopa, entacapone; Levodopa, carbidopa, odm-104; Levodopa, decarboxylase inhibitor and comt inhibitor; Levodopa-carbidopa; Levodopa-carbidopa (lc) oral encapsulated immediate release (ir) tablets; Levodopa-carbidopa immediate release (lc-ir) tablets; Levodopa-carbidopa intestinal gel; Levodopa-carbidopa multilayer extended release tablet; Levodopa-carbidopa xl tablet (m); Levodopa-carbidopa-entacapone; Levodopa/benserazide; Levodopa/benserazide 100/25 mg; Levodopa/benzeraside; Levodopa/benzerazide; Levodopa/carbidopa; Levodopa/carbidopa (4:1); Levodopa/carbidopa (sinemet); Levodopa/carbidopa 100/25; Levodopa/carbidopa hydrate; Levodopa/carbidopa solution; Levodopa/carbidopa(200mg/50mg); Levodopa/carbidopa/entacapone; Levodopa/ddci; Nacom levodopa+cardidopa; Nd0612 (levodopa/carbidopa solution); Oral levodopa and carbidopa; Oral levodopa/carbidopa; Rasagiline mesylate with levodopa; Safinamide + levodopa; Sinemet (levodopa/carbidopa); Sinemet plus (levodopa/carbidopa); Sinemet® controlled release (carbidopa/levodopa); Stalevo (levodopa/ carbidopa/ entacapone); Stalevo (levodopa/carbidopa/entacapona); Tvp-1012 (1 mg/day) with levodopa; Tvp-1012 1mg with levodopa; | D00059 |
[5] DRD1, DRD2, DRD3, DRD4, DRD5 |
[11] Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
[7] 2, 4, 6, 17, 90, 164, 201 |
67 | Levosimendan | [2] Levosimendan; Oral levosimendan; | D04720 |
[2] PDE3A, PDE3B |
[11] Apelin signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Progesterone-mediated oocyte maturation, Purine metabolism, Regulation of lipolysis in adipocytes, Renin secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
[1] 2 |
68 | Lipoic Acid | [8] Alpha lipoic acid; Alpha-lipoic acid; Alpha-lipoic acid and l-acetyl carnitine; Lipoic acid; Lipoic acid (la) with fish oil and la without fish oil; Lipoic acid and omega-3 fatty acids; Oral lipoic acid (la); R lipoic acid; | D00048 D00086 |
- |
- |
[5] 2, 5, 13, 14, 20 |
69 | Lithium carbonate | [1] Lithium carbonate; | D00801 |
- |
- |
[8] 2, 5, 7, 8, 13, 17, 19, 127 |
70 | Lithium citrate | - | D04749 |
- |
- |
[4] 2, 5, 7, 8 |
71 | Masitinib | [10] Masitinib; Masitinib (3.0); Masitinib (4.5); Masitinib (6.0); Masitinib (ab1010); Masitinib 100mg; Masitinib 200mg; Masitinib 3 mg; Masitinib 6.0 mg; Masitinib mesylate; | D10229 |
[1] KIT |
[11] Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway |
[6] 2, 5, 6, 13, 46, 96 |
72 | Medical Cannabis | - | - |
- |
- |
[6] 2, 6, 13, 90, 96, 97 |
73 | Memantine | [3] Memantine; Memantine (ebixa); Memantine hydrochloride; | D04905 D08174 |
[5] GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
[17] Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
[7] 2, 6, 8, 13, 49, 127, 205 |
74 | Methamidophos | - | - |
- |
- |
[12] 2, 11, 13, 19, 46, 49, 58, 70, 85, 98, 298, 300 |
75 | Methylcobalamin | [1] Methylcobalamin; | D03246 |
- |
- |
[1] 2 |
76 | Methylprednisolone | [29] Administration of rituximab and methylprednisolone; Corticosteroid treatment (methylprednisolone or prednisolone); Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Infliximab, methylprednisolone, methotrexate; Intravenous (i.v.) methylprednisolone 1000 mg, total 9; Intravenous methylprednisolone; Iv methylprednisolone; Iv methylprednisolone (steroids); Megadose oral methylprednisolone; Methotrexate + methylprednisolone; Methylprednisolone; Methylprednisolone (drug); Methylprednisolone (mp); Methylprednisolone (mp) or prednisone (pred); Methylprednisolone (or other glucocorticoid); Methylprednisolone bolus iv 15 mg/kg/d for 3 days.; Methylprednisolone hemisuccinate; Methylprednisolone iv; Methylprednisolone mylan générique; Methylprednisolone or budesonide; Methylprednisolone or prednisolone; Methylprednisolone pulse; Methylprednisolone sodium hemisuccinate; Methylprednisolone sodium succinate; Methylprednisolone(intravenously in the 1st-2nd-3rd month ); Methylprednisolone(intravenously in the 1st-3rd-5th month); Oral 5-asa+/-topical 5-asa+iv corticosteroids / po methylprednisolone; Prednisone (and methylprednisolone); Prednisone, methylprednisolone,cyclophosphamides; | D00407 D00751 D00979 D05000 D05001 D05002 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[36] 2, 13, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 145, 164, 220, 222, 224, 271, 283, 284, 285, 296 |
77 | Mexiletine | [1] Mexiletine; | D00639 D08215 |
[5] SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
[3] Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
[5] 1, 2, 10, 113, 114 |
78 | Midazolam | [6] Bms drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin); Midazolam; Midazolam 2 mg; Midazolam 3 mg; Montelukast, flurbiprofen, midazolam, digoxin, pravastatin and bms-986142; S-ketamine & midazolam; | D00550 D00696 D05028 |
[16] GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
[7] GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
[10] 2, 3, 6, 13, 46, 70, 96, 97, 231, 298 |
79 | Minocycline | [7] Combination of minocycline and mtx or mtx alone; Glatiramer acetate with minocycline; Lovastatin, then minocycline/lovastatin; Minocycline; Minocycline 100 mg film-coated tablets; Minocycline hydrochloride; Minocycline, then minocycline/lovastatin; | D00850 D05045 |
- |
- |
[14] 2, 6, 8, 13, 46, 84, 85, 90, 94, 162, 201, 206, 280, 299 |
80 | Moxifloxacin | [5] Avelox- moxifloxacin; Moxifloxacin; Moxifloxacin 400 mg; Moxifloxacin hydrochloride; Moxifloxacin infusion; | D00874 D08237 |
- |
- |
[8] 2, 6, 46, 49, 85, 86, 240, 299 |
81 | Mycophenolate mofetil | [17] Azathioprine or mycophenolate mofetil; Cellcept (mycophenolate mofetil); Cyclosporine combine with mycophenolate mofetil; Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate); Mycophenolate mofetil; Mycophenolate mofetil (cellcept); Mycophenolate mofetil (mmf); Mycophenolate mofetil (mmf) 3 g/day; Mycophenolate mofetil 2 g/day; Mycophenolate mofetil [cellcept]; Mycophenolate mofetil orally 1000 mg twice a day (bid); Mycophenolate mofetil plus lower dose of prednisone; Mycophenolate mofetil(mmf); Mycophenolate mofetil, low dose steroid; Mycophenolate mofetil,methotrexate; Prednisolone and mycophenolate mofetil; Prednisone and mycophenolate mofetil; | D00752 D05094 D05095 |
[2] IMPDH1, IMPDH2 |
[3] Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
[32] 2, 11, 13, 14, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 85, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
82 | Mycophenolic acid | [2] Mycophenolic acid; Mycophenolic acid mofetil; | D05096 |
[2] IMPDH1, IMPDH2 |
[3] Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
[34] 2, 11, 13, 14, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 84, 85, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 |
83 | Olanzapine | [1] Olanzapine; | D00454 D06623 |
[11] ADRA1A, ADRA1B, ADRA1D, DRD2, DRD3, DRD4, HRH1, HTR2A, HTR2B, HTR2C, HTR6 |
[16] AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Alcoholism, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Salivary secretion, Serotonergic synapse, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
[2] 2, 8 |
84 | Ozanezumab | [1] Ozanezumab; | D10331 |
[1] RTN4 |
[1] Alzheimer disease |
[1] 2 |
85 | Palmidrol | - | D08328 |
- |
- |
[1] 2 |
86 | Perampanel | [3] 2 mg perampanel; 4 mg perampanel; Perampanel; | D08964 |
[4] GRIA1, GRIA2, GRIA3, GRIA4 |
[13] Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Transcriptional misregulation in cancer, cAMP signaling pathway |
[3] 2, 6, 144 |
87 | Phenylbutyric acid | - | D05868 |
- |
- |
[10] 2, 3, 6, 8, 93, 94, 244, 251, 297, 299 |
88 | Phosphate ion | - | - |
- |
- |
[29] 2, 3, 11, 12, 13, 28, 36, 46, 49, 51, 53, 60, 62, 65, 70, 78, 81, 83, 90, 96, 97, 164, 235, 256, 283, 284, 285, 286, 299 |
89 | Pimozide | [4] Pimozide; Pimozide 2 mg per day; Pimozide 2mg/day (current) or 4 mg/day (study initiation); Pimozide 4 mg per day; | D00560 |
[2] DRD2, DRD3 |
[8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
[1] 2 |
90 | Pioglitazone | [6] Actos (pioglitazone); Pioglitazone; Pioglitazone 15 mg; Pioglitazone and tretinoin; Pioglitazone or metformin; Tretinoin and pioglitazone hcl; | D00945 D08378 |
[1] PPARG |
[9] AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer |
[17] 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 |
91 | Pleconaril | [1] Pleconaril; | D05528 |
- |
- |
[1] 2 |
92 | Pramipexole | [20] Dopamine agonists (pramipexole, ropirinole); Mirapex (pramipexole); P2b001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),; P2b001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),; Pramipexole; Pramipexole 0.125 mg tablets; Pramipexole 0.5 mg tablets; Pramipexole dihydrochloride; Pramipexole dihydrochloride extended-release tablets; Pramipexole dihydrochloride monohydrate; Pramipexole dihydrochloride monohydrate extended release; Pramipexole er; Pramipexole extended release; Pramipexole extended release tablet; Pramipexole immediate release; Pramipexole immediate release tablet; Pramipexole ir; Pramipexole or ropinirole; Pramipexole sr; R(+) pramipexole dihydrochloride monohydrate; | D00559 D05575 |
[3] DRD2, DRD3, DRD4 |
[8] Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
[2] 2, 6 |
93 | Prednisone | [57] 0 mg prednisone; 5 mg prednisone; 5-aminosalicylic acid(5-asa) and/or prednisone; 5-asa, prednisone, azathioprine or remicade; Azathioprine/prednisone; Chinese herb prescription granule plus prednisone; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Corticosteroids (prednisone or prednisolone); Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Cyclophosphamide-prednisone-azathioprine; Glucocorticoid (prednisone or prednisolone); Granulocyte-colony stimulating factor (g-csf) and prednisone; Hormone (prednisone); Hydroxychloroquine + prednisone; Leflunomide 20 mg+prednisone 0.5mg/kg/d; Methylprednisolone (mp) or prednisone (pred); Mycophenolate mofetil plus lower dose of prednisone; Oral prednisone; Oral prednisone 5mg; Over encapsulated prednisone; Prednisone; Prednisone (and methylprednisolone); Prednisone + inhibace/cozaar; Prednisone - azathioprine; Prednisone 0,5 mg/kg orally on alternate days; Prednisone 15 mg; Prednisone 5 mg; Prednisone 7.5 mg; Prednisone acetate; Prednisone acetate tablets; Prednisone alone; Prednisone and cyclophosphamide; Prednisone and mycophenolate mofetil; Prednisone and ustekinumab treatment; Prednisone arrow 20mg; Prednisone arrow 5 mg; Prednisone capsules; Prednisone discontinuation; Prednisone in full dose; Prednisone or prednisolone; Prednisone plus cyclophosphamide; Prednisone tablets usp, 1 mg; Prednisone tablets usp, 2.5 mg; Prednisone tablets usp, 5 mg; Prednisone tablets, usp; Prednisone therapy and pharmacokinetic; Prednisone treatment; Prednisone, cyclophosphamide; Prednisone, fk506, mmf; Prednisone, methylprednisolone,cyclophosphamides; Prednisone/prednisolone; Rayos (delayed-release prednisone); Sotatercept with prednisone boost; Tacrolimus combined with prednisone; Thalidomide, cyclophosphamide and prednisone; Treatment systemic therapy (prednisone); Treatment with systemic therapy (prednisone); | D00473 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[44] 2, 11, 13, 14, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 81, 84, 85, 86, 95, 96, 97, 113, 145, 162, 164, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 |
94 | Pyrimethamine | [2] Fansidar (pyrimethamine and sulfadoxine); Pyrimethamine; | D00488 |
- |
- |
[4] 2, 4, 19, 65 |
95 | Quinidine | [5] Dextromethorphan hbr and quinidine sulfate; Dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg; Dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg; Dextromethorphan/quinidine 20mg/10mg (dm/q 20mg/10mg); Quinidine; | D00642 D00643 D02272 D08458 |
[5] SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
[3] Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
[3] 2, 8, 13 |
96 | Rabeprazole | [1] Rabeprazole; | D00724 D08463 |
[2] ATP4A, ATP4B |
[4] Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
[2] 2, 51 |
97 | Ranolazine | [7] Ranolazine; Ranolazine 1000 mg; Ranolazine 1000 mg pr tablets; Ranolazine 500 mg; Ranolazine 500 mg pr tablets; Ranolazine 750 mg pr tablets; Ranolazine pr (prolonged-release) 500 mg 1 tablet bis in die and 750 mg 1 tablet bis in die; | D05700 D05701 |
- |
- |
[6] 2, 58, 86, 113, 114, 130 |
98 | Rasagiline | [16] 1.0 mg rasagiline mesylate; Group r rasagiline; Group r+ad rasagiline + antidepressant; P2b001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),; P2b001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),; Rasagiline; Rasagiline 1 mg capsule; Rasagiline 1mg tablet; Rasagiline 2 mg tablet; Rasagiline mesilate; Rasagiline mesylate; Rasagiline mesylate 1.0 mg; Rasagiline mesylate plus mirapex; Rasagiline mesylate with levodopa; Rasagiline mesylate with requip; Rasagiline tablets; | D02562 D08469 D10829 |
[1] MAOB |
[13] Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
[4] 2, 5, 6, 17 |
99 | Reldesemtiv | - | D11363 |
[1] TNNC2 |
[1] Calcium signaling pathway |
[2] 2, 3 |
100 | Ribavirin | [1] Ribavirin; | D00423 |
- |
- |
[2] 2, 96 |
101 | Riluzole | [5] Riluzole; Riluzole 50 mg; Riluzole 50 mg (part b); Riluzole oral soluble film; Riluzole oral soluble film (rosf) 50 mg; | D00775 |
[14] GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
[20] Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Retrograde endocannabinoid signaling, Systemic lupus erythematosus, Transcriptional misregulation in cancer, cAMP signaling pathway |
[7] 2, 3, 5, 8, 13, 17, 206 |
102 | Ritonavir | [9] Atazanavir (atv) + ritonavir (rtv), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (nrtis); Atazanavir/ritonavir; Lopinavir / ritonavir; Lopinavir/ritonavir; Lopinavir/ritonavir + nevirapine; Lopinavir/ritonavir + zidovudine + lamivudine; Ritonavir; Ritonavir (norvir); Saquinavir and ritonavir; | D00427 |
- |
- |
[5] 2, 86, 130, 265, 299 |
103 | Scopolamine | [1] Scopolamine; | D00138 |
[5] CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
[11] Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
[1] 2 |
104 | Serine | [4] D-serine; D-serine (~2g/day); L-serine; Serine; | D00016 |
- |
- |
[3] 2, 6, 86 |
105 | Serotonin | [2] Selective serotonin uptake inhibitors (ssri); Serotonin; | - |
- |
- |
[1] 2 |
106 | Sirolimus | [14] Rapamycin, sirolimus; Sirolimus; Sirolimus (formerly known as rapamycin); Sirolimus 0,1% crème; Sirolimus 0.2%; Sirolimus 0.4%; Sirolimus 2 mg; Sirolimus 2%; Sirolimus and hydroxychloroquine; Sirolimus oral liquid product 1mg/ml; Sirolimus, 2%; Skincerity plus sirolimus/rapamycin; Skinercity plus sirolimus/rapamycin; Topical 0.1% sirolimus; | D00753 |
[1] MTOR |
[43] AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway |
[36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
107 | Somatotropin | [2] Recombinant human somatotropin; Somatotropin; | D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[18] 2, 3, 13, 19, 46, 74, 75, 78, 96, 113, 191, 193, 195, 236, 265, 274, 276, 299 |
108 | Sulfate ion | - | - |
- |
- |
[22] 2, 6, 11, 13, 26, 34, 36, 46, 49, 60, 61, 64, 66, 79, 86, 96, 222, 226, 265, 296, 297, 299 |
109 | TRO19622 | [2] Olesoxime (tro19622); Tro19622; | - |
- |
- |
[3] 2, 3, 13 |
110 | Tacrolimus | [13] Busulfan/fludarabine phosphate/tacrolimus/methotrexate/g-csf; Interferon beta-1b and tacrolimus; Lcp-tacro (tacrolimus); Non-mtx dmards (e.g. sulfasalazine, leflunomide, bucillamine, tacrolimus, or mizoribin); Rectal tacrolimus; Tacrolimus; Tacrolimus (prograf®); Tacrolimus and mmf; Tacrolimus capsule; Tacrolimus capsules; Tacrolimus combined with prednisone; Tacrolimus prolonged-release hard capsules; Tacrolimus with methotrexate; | D00107 D08556 |
[5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
[30] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
[30] 2, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 86, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 228, 283, 284, 299 |
111 | Talampanel | [1] Talampanel; | D02696 |
[4] GRIA1, GRIA2, GRIA3, GRIA4 |
[13] Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Transcriptional misregulation in cancer, cAMP signaling pathway |
[2] 2, 6 |
112 | Tamoxifen | [3] Tamoxifen; Tamoxifen 40 mg daily for one year; Tamoxifen citrate; | D00966 D08559 |
[2] ESR1, ESR2 |
[9] Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
[4] 2, 86, 113, 227 |
113 | Tauroursodeoxycholic acid | [2] Tauroursodeoxycholic acid; Tauroursodeoxycholic acid capsules; | - |
- |
- |
[4] 2, 13, 93, 299 |
114 | Tenofovir | [10] Emtricitabine (ftc)/tenofovir disoproxil (tdf); Emtricitabine/tenofovir; Tenofovir; Tenofovir (tdf) and emtricitabine (ftc); Tenofovir alafenamide; Tenofovir alafenamide (taf); Tenofovir df; Tenofovir disoproxil; Tenofovir disoproxil fumarate; Tenofovir-emtricitabine; | D06074 |
- |
- |
[5] 2, 25, 93, 265, 325 |
115 | Tenofovir alafenamide | [2] Tenofovir alafenamide; Tenofovir alafenamide (taf); | D10428 |
- |
- |
[1] 2 |
116 | Testosterone | [7] Nebido® testosterone undecanoate 1000 mg/4 ml solution for injection; Sustanon (testosterone); Testosterone; Testosterone enanthate; Testosterone plus somatropin; Testosterone undecanoate; Transdermal testosterone gel; | D00075 D00957 D00958 D00959 D06085 D06087 |
[1] AR |
[3] Oocyte meiosis, Pathways in cancer, Prostate cancer |
[7] 1, 2, 3, 13, 78, 113, 265 |
117 | Thalidomide | [9] Fpf 300 (thalidomide); Melphalan, thalidomide and dexamethasone; Thalidomide; Thalidomide (drug); Thalidomide 100mg; Thalidomide 150mg; Thalidomide celgene - 50 mg capsula rigida - uso orale - blister (pvc/pe/aclar/alu) 28 capsule; Thalidomide pharmion; Thalidomide, cyclophosphamide and prednisone; | D00754 |
[1] TNF |
[61] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
[18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
118 | Tirasemtiv | [1] Tirasemtiv; | D10327 |
- |
- |
[1] 2 |
119 | Tocilizumab | [25] Abatacept, rituximab or tocilizumab; Corticoids+ tocilizumab 8mg/kg/4 weeks; Decrease tocilizumab, abatacept; Inn-tocilizumab; Intra-articular tocilizumab; Mra (tocilizumab); Mra(tocilizumab); Subcutaneous tocilizumab; Tocilizumab; Tocilizumab (actemra®); Tocilizumab (mra-sc); Tocilizumab + glucocorticoids (gcs); Tocilizumab + methotrexate(mtx); Tocilizumab 162 mg; Tocilizumab 162mg/0.9ml jeringa sc; Tocilizumab [roactemra/actemra]; Tocilizumab [roactemra]; Tocilizumab infusion roacemtra (eu); Tocilizumab injection; Tocilizumab prefilled syringe; Tocilizumab sc; Tocilizumab sc 162 mg/0.9 ml prefilled syringe with safety device (pfs); Tocilizumab treatment; Tocilizumab+methotrexate(mtx); Tocilizumab, abatacept; | D02596 |
[1] IL6R |
[11] Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease (NAFLD), PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
[16] 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
120 | Tretinoin | [3] Pioglitazone and tretinoin; Tretinoin; Tretinoin and pioglitazone hcl; | D00094 |
[3] PML, RARA, RARB |
[12] Acute myeloid leukemia, Endocytosis, Estrogen signaling pathway, Gastric cancer, Herpes simplex virus 1 infection, Influenza A, Non-small cell lung cancer, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Transcriptional misregulation in cancer, Ubiquitin mediated proteolysis |
[5] 2, 63, 75, 94, 231 |
121 | Triheptanoin | [4] Triheptanoin; Triheptanoin 1g/kg/day; Triheptanoin oil; Ux007 (triheptanoin); | D11465 |
- |
- |
[10] 2, 8, 120, 149, 156, 248, 256, 257, 317, 324 |
122 | Ubidecarenone | - | D01065 |
- |
- |
[12] 2, 5, 6, 8, 10, 46, 57, 86, 113, 193, 214, 215 |
123 | Valproic Acid | [3] Valproic acid; Valproic acid (vpa); Valproic acid and levocarnitine; | D00399 |
[7] ABAT, ALDH5A1, CACNA1G, CACNA1H, CACNA1I, GAD1, GAD2 |
[17] Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism |
[14] 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
124 | Vitamin E | [8] Coenzyme q10 with vitamin e; Omega-3 and vitamin e supplementation; Vitamin c 10mg/kg vitamin e 10 mg/kg; Vitamin e; Vitamin e - tgps; Vitamin e 800iu; Vitamin e supplement; Vitamin e/selenium; | D02331 |
- |
- |
[12] 2, 6, 13, 20, 46, 49, 90, 96, 97, 206, 299, 317 |
125 | Water | [13] 15 o water; 15-o labeled water; 5% glucose water solution; Dextrose, 5% in water; High water intake; Lactose in water; Pl 12185/0002 & pl 12185/0005(water for injection); Pseudoephedrine + 480 ml water; Pseudoephedrine + 50 ml water; Water; Water for injection; Water for injections; Water for injections, ep; | D00001 |
- |
- |
[22] 2, 5, 6, 13, 17, 19, 28, 35, 46, 53, 57, 63, 65, 67, 78, 84, 97, 193, 226, 271, 278, 299 |
126 | Zinc | [8] Adeno-associated virus serotype 2/6 encoding left side-zinc finger nuclease (zfn1), sb-a6p-zleft vector; Adeno-associated virus serotype 2/6 encoding right side-zinc finger nuclease (zfn2), sb-a6p-zright vector; Zinc; Zinc acetate; Zinc acetate (20mg/d); Zinc acetate dihydrate; Zinc and copper; Zinc gluconate; | - |
- |
- |
[4] 2, 19, 171, 299 |
127 | Zinc chloride | - | D02058 |
- |
- |
[4] 2, 19, 171, 299 |